Public Health News Roundup: August 15
HHS: $250M to Expand Access to High-Quality Preschools
The U.S. Department of Health and Human Services (HHS) has announced that applications are now available for the $250 million Preschool Development Grants competition, which was established to build, develop and expand voluntary, high-quality preschool programs in high-need communities for children from low- and moderate-income families. “When we invest in early education, the benefits can last a lifetime,” said HHS Secretary Sylvia M. Burwell, in a release. “Children who attend high-quality early learning and preschool programs are more likely to do well in school and secure good jobs down the road. We all gain when our country has a stronger, more productive workforce, lower crime rates, and less need for public assistance. These Preschool Development Grants will help put more children on the path to opportunity.” Read more on education.
Study: Three Common Respiratory Illnesses Linked to Higher Risk of Lung Cancer
Chronic bronchitis, emphysema and pneumonia are all tied to an increased risk of lung cancer, according to a new study in the American Journal of Respiratory and Critical Care Medicine. Researchers analyzed data on more than 250,000 people, concluding that the reason for the increased risk could relate to underlying disease mechanisms. They also said that a better understanding of the respiratory diseases could affect how doctors monitor and help patients. Read more on prevention.
FDA: More Data Needed on Painkiller’s Abuse-Deterrent Capability
The U.S. Food and Drug Administration (FDA) has requested additional study and information to determine the effectiveness of an abuse-deterrent capability in an experimental painkiller. Acura Pharmaceuticals states that its drug, which contains the common painkillers hydrocodone bitartrate and acetaminophen, cannot be abused by snorting. The drug is designed to cause a burning sensation when snorted or form a gelatinous mixture when prepared for injection. However, the drug failed in a mid-stage trial to show a statistically significant likelihood of reducing abuse. Read more on substance abuse.